98%
921
2 minutes
20
Background: Community-based rehabilitation (CBR) interventions are important for improving the well-being of people with disabilities. However, there is no universally accepted framework for evaluating these interventions, which limits their effectiveness and integration into policy.
Objectives: To explore theoretical frameworks used in evaluating CBR interventions, assessing their suitability, context-specific applicability and cultural relevance.
Method: A scoping review methodology was employed to examine the literature. Databases searched included PubMed, CINAHL, EBSCOhost and Web of Science. Broad search terms and keywords used were CBR, analytical and/or methodological and/or theoretical and/or conceptual and/or evaluation framework, impact and evaluation. Only full-text articles written in English and published between 2000 and 2020 were included. Data were analysed using a narrative synthesis method.
Results: No single framework has been widely recognised as the superior or most effective standard for evaluating CBR interventions. Instead, a combination of the CBR matrix and CBR guidelines was frequently used and adapted to be context-specific.
Conclusion: While cultural relevance and context specificity are recognised as essential to the evaluation process - and measuring outcomes at the individual level is viewed as most appropriate - there remains a need for a certain level of standardisation.
Contribution: The study highlights the need for context-specific and culturally relevant evaluation frameworks for CBR interventions, including appropriate outcome measures and/or evaluation instruments.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339764 | PMC |
http://dx.doi.org/10.4102/ajod.v14i0.1546 | DOI Listing |
Ann Med
December 2025
Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Background: Although some studies have indicated that CDK4/6 inhibitors are beneficial for the progression-free survival (PFS) and overall survival (OS) in breast cancer, evidence regarding the assessment of clinical response remains insufficient. Therefore, this study aims not only to evaluate the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR(+)/HER2(-) metastatic breast cancer, but also to analyze the objective response rate (ORR) and clinical benefit rate (CBR), providing comprehensive clinical outcome insights.
Materials And Methods: A literature search was performed in PubMed, Embase, Cochrane Library, and ClinicalTrials.
Anal Chim Acta
November 2025
Department of Physics, University of Lucknow, Lucknow, India; Department of Physics and Astrophysics, University of Delhi, India. Electronic address:
Background: Water contamination is a global challenge, primarily due to heavy metal ions like lead (Pb), iron (Fe), cadmium (Cd), andmercury (Hg) as well as dyes. These pollutants enter the ecosystem from industrial waste and runoff, accumulate in the environment and pose a high risk to humans, animals and plants. Various sensors, such as colorimetric sensors, and electrochemical sensors have been developed to detect these ions and dyes.
View Article and Find Full Text PDFDrugs
September 2025
Research Unit in Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium.
Objectives: Our objective was to systematically synthesize and evaluate the existing evidence from meta-syntheses (systematic reviews and meta-analyses) reporting on the safety of celecoxib in adults with chronic musculoskeletal disorders.
Methods: We conducted a comprehensive literature search in November 2024 across MEDLINE, Cochrane Central, and Scopus databases, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines for umbrella reviews. Only systematic reviews and meta-analyses involving celecoxib safety in osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis were included.
Ther Adv Med Oncol
August 2025
Department of Medical Oncology, Fudan University Shanghai Cancer Center, 130 Dongan Road, Xuhui District, Shanghai 200032, China.
Background: Utidelone (UTD1), a genetically engineered epothilone derivative, has been approved in China for use in combination with capecitabine in treating metastatic breast cancer (MBC) patients previously treated with anthracyclines or taxanes.
Objectives: To evaluate the real-world efficacy and safety of UTD1 in Chinese patients with MBC and to explore potential predictors of therapeutic effectiveness.
Design: A multicenter, retrospective, real-world study.
EClinicalMedicine
September 2025
HUTCHMED, Shanghai, China.
Background: Tazemetostat, the first enhancer of zeste homolog 2 (EZH2) inhibitor approved by the U.S. Food and Drug Administration, has shown efficacy in a global population with relapsed or refractory (R/R) follicular lymphoma (FL).
View Article and Find Full Text PDF